

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CK Life Sciences Int'l. (Holdings) Inc.

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8222)

APPOINTMENT OF DIRECTOR

The Board of Directors (the “Board”) of CK Life Sciences Int'l., (Holdings) Inc. (the “Company”) announces that Mr. Colin Stevens Russel has been appointed an Independent Non-executive Director of the Company with effect from 1st January, 2005.

Mr. Colin Stevens Russel, aged 64, is the founder and Managing Director of Emerging Markets Advisory Services Ltd., a company which provides advisory services to organizations on business strategy and planning, market development, competitive positioning and risk management. He was the Canadian Ambassador to Venezuela, Consul General for Canada in Hong Kong, Director for China of the Department of Foreign Affairs, Ottawa, Director for East Asia Trade in Ottawa, Senior Trade Commissioner for Canada in Hong Kong, Director for Japan Trade in Ottawa, and was in the Trade Commissioner Service for Canada in Spain, Hong Kong, Morocco, the Philippines, London and India. He was Project Manager for RCA Ltd in Liberia, Nigeria, Mexico and India and electronic equipment development engineer in Canada with RCA Ltd and in Britain with Associated Electrical Industries. Mr. Russel is a Professional Engineer and Qualified Commercial Mediator. He received his Master’s degree in Business Administration and a degree in electronics engineering from McGill University, Canada. Mr. Russel is concurrently appointed an Independent Non-executive Director of Cheung Kong Infrastructure Holdings Limited. Mr. Russel does not have any relationship with any other Directors, senior management, management shareholders, substantial shareholders or controlling shareholders of the Company. He does not have interests in shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance. There is no service contract entered into between Mr. Russel and the Company. Pursuant to the Company’s Articles of Association, Mr. Russel will hold office until the next annual general meeting of the Company and will then be eligible for re-election. Mr. Russel will receive a Director’s fee of HK\$70,000 per annum and a further fee of HK\$70,000 and HK\$20,000 per annum for being a member of the Audit Committee and the Remuneration Committee of the Company respectively. Such fees are subject to review by the Board from time to time pursuant to the power given to it under the Articles of Association of the Company.

Save as disclosed herein, there are no other matters relating to the above appointment of Director that need to be brought to the attention of the shareholders of the Company.

By Order of the Board
CK Life Sciences Int'l, (Holdings) Inc.

Eirene Yeung
Company Secretary

Hong Kong, 31st December, 2004

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel, Dr. Pang Shiu Fun, Dr. Chu Kee Hung and Mr. Lam Hing Chau, Leon; and the Non-executive Directors are Mr. Kwan Chiu Yin, Robert (Independent Non-executive Director), Mr. Peter Peace Tulloch, Professor Wong Yue-chim, Richard (Independent Non-executive Director) and Mrs. Kwok Eva Lee (Independent Non-executive Director).

This announcement, for which the Directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at www.hkgem.com for at least 7 days from the date of its posting and on the website of the Company at www.ck-lifesciences.com.